Debt-to-equity of scPharmaceuticals Inc. from 30 Sep 2018 to 30 Jun 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
scPharmaceuticals Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2018 to 30 Jun 2025.
  • scPharmaceuticals Inc. Debt-to-equity for the quarter ending 30 Jun 2025 was 2196%, a 1077% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

scPharmaceuticals Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q2 2025 2196% +2010% +1077% 30 Jun 2025
Q1 2025 708% +582% +464% 31 Mar 2025
Q4 2024 384% +288% +300% 31 Dec 2024
Q3 2024 257% +176% +218% 30 Sep 2024
Q2 2024 187% +116% +164% 30 Jun 2024
Q1 2024 126% +62% +98% 31 Mar 2024
Q4 2023 96% +41% +73% 31 Dec 2023
Q3 2023 81% +37% +84% 30 Sep 2023
Q2 2023 71% +30% +74% 30 Jun 2023
Q1 2023 63% +25% +66% 31 Mar 2023
Q4 2022 55% +19% +52% 31 Dec 2022
Q3 2022 44% +9% +27% 30 Sep 2022
Q2 2022 41% +8% +25% 30 Jun 2022
Q1 2022 38% +8% +26% 31 Mar 2022
Q4 2021 36% +4% +13% 31 Dec 2021
Q3 2021 35% -1% -2% 30 Sep 2021
Q2 2021 33% -8% -19% 30 Jun 2021
Q1 2021 30% -14% -31% 31 Mar 2021
Q4 2020 32% -5% -14% 31 Dec 2020
Q3 2020 35% +6% +18% 30 Sep 2020
Q2 2020 40% +18% +77% 30 Jun 2020
Q1 2020 44% +24% +120% 31 Mar 2020
Q4 2019 38% +20% +111% 31 Dec 2019
Q3 2019 30% +13% +77% 30 Sep 2019
Q2 2019 23% 30 Jun 2019
Q1 2019 20% 31 Mar 2019
Q4 2018 18% 31 Dec 2018
Q3 2018 17% 30 Sep 2018
* An asterisk sign (*) next to the value indicates that the value is likely invalid.